Cited by 978Pharmaceutical Economics and PolicyBiosimilars and Bioanalytical MethodsMonoclonal and Polyclonal Antibodies Research

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Biopharmaceutical benchmarks 2018

Walsh, Gary·2018·Nature Biotechnology

DOI 10.1038/nbt.4305

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1038/nbt.4305

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Gene therapy clinical trials worldwide to 2017: An update
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3015 · Cited by 903
Clinical Pharmacology and Translational Aspects of Bispecific Antibodies
Trivedi, A., Stienen, S., Zhu, M., Li, H., Yuraszeck, T., Gibbs, J., Heath, T., Loberg, R., & Kasichayanula, S. (2017) · Clinical and Translational Science · doi:10.1111/cts.12459 · Cited by 76

Flagged first, then by citations

Show all 3 references

Research works printed but not linked: 11

Walsh, G. Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 32, 992–1000 (2014). · DOI · Paper page
Walsh, G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28, 917–924 (2010). · DOI
Walsh, G. Biopharmaceutical benchmarks 2006. Nat. Biotechnol. 24, 769–776 (2006). · DOI
Bertolini, L.R. et al. The transgenic animal platform for biopharmaceutical production. Transgenic Res. 25, 329–343 (2016). · DOI
Park, T.S. et al. Deposition of bioactive human epidermal growth factor in the egg white of transgenic hens using an oviduct-specific minisynthetic promoter. FASEB J. 29, 2386–2396 (2015). · DOI
Miliotou, A.N. & Papadopoulou, L.C. CAR T-cell therapy: a new era in cancer immunotherapy. Curr. Pharm. Biotechnol. 19, 5–18 (2018). · DOI
Kaplon, H. & Reichert, J.M. Antibodies to watch in 2018. MAbs 10, 183–203 (2018). · DOI
Zheng, P.P., Kros, J.M. & Li, J. Approved CAR-T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov. Today 23 1175–1182 (2018). · DOI
Labanieh, L., Majzner, R.G. & Mackall, C.L. Programming CAR-T cells to kill cancer. Nat. Biomed. Eng. 2, 377–391 (2018). · DOI
Köhl, U., Arsenieva, S., Holzinger, A. & Abken, H. CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications. Hum. Gene Ther. 29, 559–568 (2018). · DOI
Klinger, M., Benjamin, J., Kischel, R., Stienen, S. & Zugmaier, G. Harnessing T cells to fight cancer with BiTE® antibody constructs—past developments and future directions. Immunol. Rev. 270, 193–208 (2016). · DOI

Sorted by citations

Items 601–700 of 849

Modeling and Simulation of Upstream and Downstream Processes for Monoclonal Antibody Production
Wahlgreen, M. R., Meyer, K., Ritschel, T., Engsig-Karup, A., Gernaey, K., & Jørgensen, J. B. (2022) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2022.07.523 · Cited by 4
“Monoclonal antibodies (mAbs) is a class of biopharmaceuticals representing the 6 top-selling biopharmaceutical products in 2017 (Walsh, 2018).”
Background
Glycosylation Profiling of Glycoproteins Secreted from Cultured Cells Using Glycan Node Analysis and GC-MS.
de León, J. S. A. D., & Borges, C. R. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1241-5_22 · Cited by 4
Method to transfer Chinese hamster ovary (CHO) batch shake flask experiments to large-scale, computer-controlled fed-batch bioreactors
Klaubert, S. R., Chitwood, D. G., Dahodwala, H., Williamson, M., Kasper, R., Lee, K. H., & Harcum, S. W. (2021) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2021.05.005 · Cited by 4
Next-Generation Cell Engineering Platform for Improving Recombinant Protein Production in Mammalian Cells
Shin, S. W., Kyeong, M., & Lee, J. S. (2021) · Cell engineering · doi:10.1007/978-3-030-79871-0_7 · Cited by 5
Intensified and Continuous mAb Production with Single-Use Systems
Müller, J., Teale, M., Steiner, S., Junne, S., Neubauer, P., Eibl, D., & Eibl, R. (2021) · Cell Engineering · doi:10.1007/978-3-030-79871-0_13 · Cited by 4
Membrane Proteins as Targets for Biological Drugs
Sood, V. D., & Gross, A. W. (2019) · Springer eBooks · doi:10.1007/978-981-13-9077-7_3 · Cited by 6
Gene Therapy
del Pozo‐Rodríguez, A., Rodríguez‐Gascón, A., Rodríguez-Castejón, J., Vicente-Pascual, M., Gómez-Aguado, I., Battaglia, L., & Solinís, M. Á. (2019) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2019_109 · Cited by 16
Do We Really Need End‐To‐End Continuous Processing for Biomanufacturing of Monoclonal Antibodies?
Rathore, A., Metya, S., & Nitika, N. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.70147 · Cited by 3
Engineering a single-chain vascular endothelial growth factor with enhanced physiological stability for accelerating wound healing
Wang, Y.-W., Chen, T. C.-Y., & Luo, C. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.146281 · Cited by 2
Therapeutic potential and clinical translation of nanodrugs: A path forward- case studies from bench to bedside
Al‐Sulaiti, F. K., & Şahin, S. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107252 · Cited by 2
Therapeutic glycoprotein hormones: Considerations for the use of in vitro alternatives to in vivo potency assays.
Cowper, B., Moore, M., & Burns, C. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116895 · Cited by 3
Cell clone selection—impact of operation modes and medium exchange strategies on clone ranking
Dorn, M., Ferng, C., Klottrup‐Rees, K., Lee, K. M. L., & Micheletti, M. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1479633 · Cited by 2
“This represents a 3-to 4-fold increase compared to the previous decade (2005 – 2014; Walsh, 2018; Walsh and Walsh, 2022).”
Selective Recruitment of a Synthetic Histone Acetyltransferase Can Boost CHO Cell Productivity
Butterfield, S. P., Sizer, R. E., Saunders, F. L., & White, R. J. (2024) · Biotechnology Journal · doi:10.1002/biot.202400474 · Cited by 4
Streamlined Clarification and Capture Process for Monoclonal Antibodies Using Fluidized Bed Centrifugation and Multi‐Column Chromatography With Membrane Adsorbers
Schmitz, F., Saballus, M., Kruse, T., Minceva, M., & Kampmann, M. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28884 · Cited by 3
“After mAb production in fed ‐ batch bioreactors using Chinese Hamster Ovary (CHO) cell lines (Walsh 2018; Xiang et al. 2024), the mAb downstream process starts with separating cells and cell debris of cells disrupted during the cultivation from the mAb ‐ containing fluid (Liu et al. 2010).”
Cascade Enzymes Confined in DNA Nanoanchors for Antitumor Therapy
Wang, D., Zhou, X. M., Huang, M., Duan, J., Qiu, Y., Yi, H., Wang, Y., Xue, H., Zhang, J., Yang, Q., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c09835 · Cited by 4
Novel and effective screening system for recombinant protein production in CHO cells
Zhang, J., Yang, W., Zhang, L., Li, W., Zhang, J., Wang, X.-Y., & Wang, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-71915-0 · Cited by 2
SPEED‐MODE cell line development (CLD): Reducing Chinese hamster ovary (CHO) CLD timelines via earlier suspension adaptation and maximizing time spent in the exponential growth phase
Ganapathy, K., Lam, C., Tsukuda, J., Sargon, A., Nava, A., Harms, P. D., Shen, A., Barnard, G. C., & Misaghi, S. (2024) · Biotechnology progress (Print) · doi:10.1002/btpr.3479 · Cited by 3
Chromatographic single-step purification of tagless proteins using gp41-1 split inteins
Knapp, M., Kohl, V., Best, T., Rammo, O., & Ebert, S. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1319916 · Cited by 3
“These could include peptide scaffolds, oligonucleotides, hybrids, molecular conjugates and other molecules that tackle the resolution of current downstream solutions due to their high diversity and complexity (Valeur et al., 2017; Walsh, 2018).”
Background
Optimization of Factors Affecting the Efficiency of Agrobacterium-Mediated Transformation of Wolffia arrhiza
Shvedova, A., Khvatkov, P. A., & Dolgov, S. (2023) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683823090089 · Cited by 3
Holistic in silico developability assessment of novel classes of small proteins using publicly available sequence-based predictors
Pais, D. A. M., Mayer, J.-P. A., Felderer, K., Batalha, M. B., Eichner, T., Santos, S. T., Kumar, R., da Silva, S. R. A., & Kaufmann, H. (2024) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-024-00569-x · Cited by 1
“Their ability to recognize and bind to specific antigens with high affinity enabled numerous clinical applications, from immune checkpoint inhibitors in cancer therapy to immune modulators in autoimmune diseases [3].”
Modeling of bioprocess pre‐stages for optimization of perfusion profiles and increased process understanding
Pogodaev, A. A., Rodríguez, T. H., Li, M., & Münzer, D. G. G. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28576 · Cited by 3
“Development and manufacturing of biologics is associated with high production process costs, which translates to the high cost of the drug on the market (Stiff et al., 2019; Walsh, 2018).”
Background
Heterologous Expression of Fungal L-Asparaginase: A Systematic Review
Andrade, K. C. R., de Abreu, J. A. C., Guimarães, M. B., Abrunhosa, L. S., Rodrigues, A. L. L., Fonseca-Bazzo, Y. M., Silveira, D., Souza, P. M., & Magalhães, P. O. (2023) · Future Microbiology · doi:10.2217/fmb-2023-0131 · Cited by 5
Design, structure and plasma binding of ancestral β-CoV scaffold antigens
Hueting, D., Schriever, K., Sun, R., Vlachiotis, S., Zuo, F., Du, L., Persson, H., Hofström, C., Ohlin, M., Wallden, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42200-x · Cited by 4
“A major bottleneck limiting the full potential of biopharmaceuticals is low protein stability, reducing both shelf-life and potency, as in vivo residence time is linked to immunogenic potential 37 .”
Stoichiometric expression of messenger polycistrons by eukaryotic ribosomes (SEMPER) for compact, ratio-tunable multi-gene expression from single mRNAsPreprint
Duan, M.-T., Dev, I., Lu, A., You, M.-Y., & Shapiro, M. (2023) · bioRxiv · doi:10.1101/2023.05.26.541240 · Cited by 3
Isothermal denaturation fluorimetry vs Differential scanning fluorimetry as tools for screening of stabilizers for protein freeze-drying: human phenylalanine hydroxylase as the case study.
Leandro, P., Lino, P. R., Lopes, R. R., Leandro, J., Amaro, M. P., Sousa, P., Vicente, J. B., & Almeida, A. J. (2023) · European journal of pharmaceutics and biopharmaceutics · doi:10.2139/ssrn.4358312 · Cited by 3
Rapid Identification of Chinese Hamster Ovary Cell Apoptosis and Its Potential Role in Process Robustness Assessment
Xiao, S., Li, Q., Jiang, J., Huo, C., Chen, H., & Guo, M. (2023) · Bioengineering · doi:10.3390/bioengineering10030357 · Cited by 3
“In 2018, 57 of 68 commercially available monoclonal antibodies were produced in CHO cells and generated an approximately USD 107 billion market [3].”
Background
Sensitive real-time on-line estimator for oxygen transfer rates in fermenters
Trout, M. A., Harcum, S. W., & Groff, R. E. (2022) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2022.09.005 · Cited by 3
Toxicity Profiling of Bacterial Inclusion Bodies in Human Caco-2 Cells
Barguilla, I., Unzueta, U., Carratalá, J. V., Cano‐Garrido, O., Villaverde, A., Hernández, A., & Ferrer‐Miralles, N. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.842256 · Cited by 4
“However, although the steady increase in mAbs approvals favors the trend toward mammalian over nonmammalian expression hosts (Walsh, 2018), in cancer therapies, prokaryotic host-derived products account for more than 60% of marketed products (Sanchez-Garcia et al., 2016).”
Background
Coupling CRISPR interference with FACS enrichment: New approach in glycoengineering of CHO cell lines for therapeutic glycoprotein production
Glinšek, K., Kramer, L., Krajnc, A., Kranjc, E., Pirher, N., Marušič, J., Hellmann, L., Podobnik, B., Štrukelj, B., Ausländer, D., et al. (2022) · Biotechnology Journal · doi:10.1002/biot.202100499 · Cited by 3
“[1,2] The survey of the biopharmaceuticalmarket approvals between 2014 and 2018, showed the predominance of protein-based therapeutics among biopharmaceutical approvals, which is likely to remain the reality in the near future.[3] The same survey period”
Background
Establishment of serum-free adapted Chinese hamster ovary cells with double knockout of GDP-mannose-4,6-dehydratase and GDP-fucose transporter
Misaki, R., Iwasaki, M., Takechi, H., Yamano, N., Ohashi, T., Kajiura, H., & Fujiyama, K. (2022) · Cytotechnology · doi:10.1007/s10616-021-00501-3 · Cited by 4
“These products include various proteins such as antibodies, enzymes, hormones, cytokines, growth factors, and coagulation factors (Dumont et al. 2016; Walsh 2018).”
Background
Exploitation of the ribosomal protein L10 R98S mutation to enhance recombinant protein production in mammalian cells
Verbelen, B., Girardi, T., Sulima, S. O., Vereecke, S., Verstraete, P., Verbeeck, J., Royaert, J., Cinque, S., Montanaro, L., Penzo, M., et al. (2022) · Engineering in Life Sciences · doi:10.1002/elsc.202100124 · Cited by 4
“The approval of the first mammalian cell derived recombinant therapeutic, tissue plasminogen factor (tPA), in 1986 has heralded the rise of mammalian cell lines for biopharmaceutical production [1,6].”
Background
The Structure of T-DNA Insertions in Transgenic Tobacco Plants Producing Bovine Interferon-Gamma
Burlakovskiy, M., Saveleva, N., Rumyantsev, A., Yemelyanov, V., Padkina, M., & Lutova, L. (2022) · Applied Sciences · doi:10.3390/app12020761 · Cited by 3
“Almost a third of all pharmaceuticals in development are of a protein nature (for example, antibodies, vaccines, enzymes, hormones, cytokines, and growth factors), and their share continues to grow [1,2].”
Background
Traceable impedance-based single-cell pipetting, from a research set-up to a robust and fast automated robot: DispenCell-S1.
Hannart, H., Berger, A., Aeberli, L., Forchelet, D., Uffer, N., Muller, G., Barrandon, Y., Renaud, P., & Bonzon, D. (2021) · SLAS technology · doi:10.1016/j.slast.2021.12.003 · Cited by 3
The effect of the composition of polysorbate 80 grades on their physicochemical properties.
Kollamaram, G., & Williams, G. R. (2021) · International Journal of Pharmaceutical Excipients · doi:10.66617/001c.95035 · Cited by 3
Professional skills of speech therapist in special education centres of Punjab, Pakistan
Mumtaz, A., Saeed, B., & Khan, M. A. (2021) · Journal of Humanities Social and Management Sciences (JHSMS) · doi:10.47264/idea.jhsms/2.1.2 · Cited by 3
“Style schooling includes students on a daily basis with trend/shared environments, while specialized education is focused on asset adjustment in a passive activation context, teaching methodological plans, and analytical exercises (Walsh, 2018).”
Background
DetectIS: a pipeline to rapidly detect exogenous DNA integration sites using DNA or RNA paired-end sequencing data
Grassi, L., Harris, C. L., Zhu, J., Hardman, C. H., & Hatton, D. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab366 · Cited by 5
“Therapeutic proteins with complex post-translational modifications are normally expressed in mammalian cell lines (Walsh, 2018; Zhu and Hatton, 2018).”
Background
Mathematical model of the multi-amino acid multi-transporter system predicts uptake flux in CHO cells
Sreejan, A., Gadgil, M., & Gadgil, C. J. (2021) · bioRxiv · doi:10.1101/2021.04.26.441392 · Cited by 3
Effect of a Neuropilin-1-Derived Virus Receptor Trap on Enterovirus A71 Infection In Vitro
Wang, H.-C., Huang, P.-N., Hung, H., Tseng, S.-N., Chang, C.-C., Tsai, Y.-R., Wang, Y., Shih, S., & Hsu, J. T.-A. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00695-20 · Cited by 6
“Prominent examples are soluble tumor necrosis factor-alpha (TNF- ) receptors, such as etanercept, or VEGF trap, such as aflibercept (19).”
Background
Biotherapeutic Products, Cellular Factories, and Multiomics Integration in Metabolic Engineering
Anh, N. H., Min, J. E., Kim, S. J., & Long, N. P. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0112 · Cited by 3
“Multiple glycoforms, as well as accompanied degradation products and oxidation and/or acetylation modiﬁcations of monoclonal antibody (Trastuzumab), recombinant human interferon-b , and recombinant human erythropoietin, have been successfully characterized using CE–MS (Haselberg et al., 2013, 2018).”
Contribution of Intrinsic Fluorescence to the Design of a New 3D-Printed Implant for Releasing SDABS
Nicolas, A., Dejoux, A., Poirier, C., Aubrey, N., Péan, J., & Velge-Roussel, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100921 · Cited by 5
“These innovations focus on the development of enhanced binding domains, multi-specificity, Fc engineering, and chemical engineering to link proteins to highly potent active pharmaceutical ingredients (APIs) [1].”
BackgroundInfluential
Native high-resolution mass spectrometry analysis of noncovalent protein complexes up to 450 kDa.
Chen, Z., Kellie, J. F., Hottenstein, C., & Szapacs, M. E. (2020) · Bioanalysis · doi:10.4155/bio-2020-0145 · Cited by 3
Engineered human FcγRIIa fusion: A novel strategy to extend serum half‐life of therapeutic proteins
Jo, M., Ko, S., Hwang, B., Min, S., Ha, J. Y., Lee, J. C., Jang, S., & Jung, S. T. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27374 · Cited by 3
“As of December 2018, over 370 biopharmaceutical products were approved by the United States Food Drug Administration and the European Medical Agency, and 112 products were commercialized from 2015 to July 2018 (Walsh, 2018).”
Background
Charge Variants Analysis of Recombinant Monoclonal Antibodies
Torkashvand, F., & Vaziri, B. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.20.003395 · Cited by 3
“They have incredible therapeutic and commercial value which make them among the top 10 best sellers of pharmaceuticals for several past years [1].”
Background
Recent developments in China’s biopharmaceutical industry (2012-2017)
Conlé, M. (2019) · Journal of Science and Technology Policy Management · doi:10.1108/jstpm-11-2018-0106 · Cited by 3
Peptide Nanoparticles for Gene Packaging and Intracellular Delivery
Vila-Gómez, P., Noble, J. E., & Ryadnov, M. G. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0928-6_3 · Cited by 9
NMR in the Characterization of Complex Mixture Drugs
Guerrini, M., Rudd, T. R., & Yates, E. A. (2019) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-11751-1_7 · Cited by 3
Machine Learning-based Prediction of the Long-term Stability of Chinese Hamster Ovary Cells due to Epigenetic ChangesPreprint
Seber, P., & Braatz, R. D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.14.643414 · Cited by 2
“Biopharmaceuticals are an important class of drugs and were 66% of all new drug approvals by the U.S. FDA in 2017 [1, 2].”
Building a programmable protein factory: Recent advances in expression element engineering for Komagataella phaffii
Song, Y., Zeng, Z., Pan, L., Liao, A., Liu, N., Huang, J., Tian, H., & Wang, X. E. (2026) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2026.05.011 · Cited by 2
Recombinant Protein Drugs: A 2025 Update
López‐Laguna, H., Parladé, E., Favaro, M. T. D. P., Palacin, C., Voltà‐Durán, E., Ferrer‐Miralles, N., Corchero, J. L., Rodríguez‐Rodríguez, R., Vázquez, E., Unzueta, U., et al. (2026) · BioDrugs · doi:10.1007/s40259-026-00783-z · Cited by 3
“Production-related heterogeneity represents an additional challenge, as it can affect stability, pharmacokinetics, and immunogenicity [95].”
Influential
From pharmaceutical paradigms to scalable production: Re-engineering growth factor production for cultivated meat
Mi, J., Vajravel, S., Huang, J., Dao, N. H., Cao, J., Chen, K., Zhang, D., & Zhou, W. (2026) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2026.105831 · Cited by 1
Harnessing engineered cyanobacteria for next-generation therapeutics
Bhardwaj, A., & Mishra, A. K. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04790-0 · Cited by 2
“Figure 3 provides a schematic representation of this design-guided approach to cyanobacterial biomanufacturing by integrating Codon optimisation and metabolic burden issues synthetic biology and advanced manufacturing literature (Walsh et al. 2018).”
Toward Sustainable Testosterone Manufacturing: Green Chemistry and Microbial Biotransformation Approaches
Fernández-Cañón, J. M., & Chamizo‐Ampudia, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052444 · Cited by 2
“Nevertheless, beyond technological development, regulatory acceptance of genetically modified microorganisms (GMOs) for pharmaceutical applications remains a critical constraint [162].”
Proteomics Strategies for Mass Spectrometry Analysis of Host Cell Proteins in Monoclonal Antibody Bioprocessing
Cao, H., Xiong, J., Su, Y., Liu, X., Tang, T., Tang, Y., Yu, W. C., Yan, L., & Li, D. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c01041 · Cited by 3
Genome-Wide Landscape of Position Effect Variegation in Pichia pastoris
Yao, X., Chen, B.-S., Zhang, Z., Gao, W., Zhang, Q., Yao, Y.-P., Pan, Y.-Y., & Liu, G. (2026) · Journal of Fungi · doi:10.3390/jof12020136 · Cited by 2
“Due to its convenient genetic manipulation, simple culture requirements, and high-density fermentation, P. pastoris is one of the most widely used eukaryotic expression systems for producing foreign proteins [2–5].”
In Silico Identification of Antiviral Peptides as Potential Leads Against Sudan Ebolavirus VP‐40
Omara, B., Kiyimba, K., Fofana, F., Diabaté, O., Odur, W., Jjingo, D., Iramiot, J., Draleru, P., Achia, J., Shafiq, M., et al. (2026) · BioMed Research International · doi:10.1155/bmri/2204127 · Cited by 2
Data-Driven Yield Improvement in Upstream Bioprocessing of Monoclonal Antibodies: A Machine Learning Case Study
Strüssmann, B. R., de Queiroz, A. R., & Hvam, L. (2025) · Processes · doi:10.3390/pr13113394 · Cited by 2
Effect of temperature on the aggregation of an Fc-fusion protein under agitation
Wang, Z., Gambe-Gilbuena, A., Unzai, S., Uchiyama, S., & Torisu, T. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107320 · Cited by 1
A Review on Economic Benefits and Impact of Biosimilars on Healthcare System
Gunnam, S., Fathema, K., Nijhawan, M., Venna, R. S. A., & Aleti, R. (2025) · Journal of Pharma Insights and Research · doi:10.69613/8mvctk45 · Cited by 2
“Biological therapeutics, derived from living organisms through complex biotechnological processes, have revolutionized the treatment landscape for numerous chronic and life-threatening conditions [1].”
Reimagining biomanufacturing: scalable and safe plant-based systems for next-generation biopharmaceuticals
Ko, K. S., Choi, H. N., Yoo, J. Y., & Lee, K. O. (2025) · Plant Biotechnology Reports · doi:10.1007/s11816-025-00993-x · Cited by 1
“However, between 2018 and 2022, this figure declined to around 67%, reflecting a shift toward alternative systems for simpler biologics (Walsh 2018; Walsh and Walsh 2022).”
Identification of Loci with High Transgene Expression in CHO Cells
Tasan, I., Eres, I. E., Wei, C., Bryant, E. E., Brisan, E., & Hubert, R. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00678 · Cited by 3
Autonomous Abiotic Thermal Protectant for Immunoglobulin G: Reducing the Need for Cold Chain Storage
Chou, B., Dalal, R. J., & Shea, K. J. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.4c01492 · Cited by 2
Predictive mechanistic model for separation of monoclonal antibody, fab fragment, and aggregate species on multimodal chromatography
Shekhawat, L. K., Markle, T., Maloisel, J.-L., & Malmquist, G. (2025) · Biotechnology progress (Print) · doi:10.1002/btpr.70022 · Cited by 2
Improved Expression of Aggregation-Prone Tau Proteins Using a Spidroin-Derived Solubility Tag
Muwonge, K., Yaman, B., Mészáros, A., Russo, G., Volkov, A. N., & Tompa, P. (2024) · Separations · doi:10.3390/separations11070198 · Cited by 1
“In the pharmaceutical industry, biopharmaceuticals produced and purified as recombinant proteins are taking center stage to curb the growing need for more bioactive products on the market [11].”
Background
Time-resolved fluoroimmunoassay for Aspergillus detection based on anti-galactomannan monoclonal antibody from stable cell line.
Wang, W.-J., Liu, C.-L., Zhang, X., Yan, J., Zhang, J.-X., You, S.-P., Su, R.-X., & Qi, W. (2024) · Analytical Biochemistry · doi:10.1016/j.ab.2024.115494 · Cited by 2
Adaptive modeling optimized by the data fusion strategy: Real‐time dying cell percentage prediction using capacitance spectroscopy
Wu, S., Ketcham, S. A., Corredor, C., Both, D., Zhao, Y., Drennen, J., & Anderson, C. A. (2024) · Biotechnology progress (Print) · doi:10.1002/btpr.3424 · Cited by 2
Compaction Properties of Particulate Proteins in Binary Powder Mixtures with Common Excipients
Holmfred, E., Hirschberg, C., & Rantanen, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010019 · Cited by 2
“Although the number of approved medicines containing proteins is increasing, the delivery of proteins remains challenging given the low absorption and related poor bioavailability of peptides and proteins [1,3,9,10].”
Background
Inefficient transcription is a production bottleneck for artificial therapeutic BiTE® proteins
Jerabek, T., Burkhart, M., Goetz, S., Greck, B., Menthe, A., Neef, R., & Otte, K. (2023) · New Biotechnology · doi:10.1016/j.nbt.2023.12.008 · Cited by 2
Initial prescriptions and medication switches of biological products: an analysis of prescription pathways and determinants in the Swiss healthcare setting
Wirth, K., Boes, S., Näpflin, M., Huber, C., & Blozik, E. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-077454 · Cited by 2
Application of Machine Learning in Ensuring Viral Safety of Biotherapeutics: Case Study Demonstrating Prediction and Optimization of Viral Clearance Performance of Anion Exchange Chromatography
Agarwal, H., Wang, X., Kulkarni, N., Tao, S., & Demers, C. (2023) · Social Science Research Network · doi:10.2139/ssrn.4385374 · Cited by 2
Effects of various disaccharide adaptations on recombinant IgA1 production in CHO-K1 suspension cells
Choa, J. B. D., Sasaki, T., Kajiura, H., Ikuta, K., Fujiyama, K., & Misaki, R. (2023) · Cytotechnology · doi:10.1007/s10616-023-00571-5 · Cited by 2
“Among these cell lines, Chinese hamster ovary (CHO) cells are used to produce 84% of the therapeutic proteins, and most of them are recombinant antibodies (Walsh 2018).”
Background
Taylor Vortex-Based Protein Crystal Nucleation Enhancement and Growth Evaluation in Batchwise and Slug Flow Crystallizers
Tao, T.-T., Li, B., Jia, S., Chen, M.-Y., Gao, Z., & Gong, J.-B. (2023) · Chemical engineering research & design · doi:10.1016/j.cherd.2023.03.044 · Cited by 2
Capillary liquid chromatography coupled with mass spectrometry for analysis of nanogram protein quantities on a wide-pore superficially porous particle column in top-down proteomics
Lignières, L., Legros, V., Khelil, M., Sénécaut, N., Lauber, M. A., Camadro, J., & Chevreux, G. (2022) · Journal of Chromatography B · doi:10.1016/j.jchromb.2022.123566 · Cited by 6
Availability and Affordability of Therapeutic Monoclonal Antibodies After the New Medical Reform in Hubei Province, China
Ding, Y.-F., Zhang, J.-W., Xia, M.-J., Wu, G., Li, W.-J., Feng, D., & Gong, S.-W. (2022) · Current Medical Science · doi:10.1007/s11596-022-2677-2 · Cited by 2
Artificial induction of chromosome aneuploidy in CHO cells alters their function as host cells
Yamano, N., Nakanishi, Y., Tanaka, W., Lai, Y., Yamazaki, M., Zenner, L., Hata, H., & Ōmasa, T. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28289 · Cited by 3
“Biotechnology and Bioengineering published by Wiley Periodicals LLC. from 2011 to 2017 (Walsh, 2018).”
BackgroundInfluential
A switchable secrete-and-capture system enables efficient selection of Pichia pastoris clones producing high yields of Fab fragments.
Gätjen, D., Wieczorek, M., Listek, M., Tomszak, F., Nölle, V., Hanack, K., & Droste, M. (2022) · JIM - Journal of Immunological Methods · doi:10.1016/j.jim.2022.113383 · Cited by 2
Crystal structure of ultra-humanized anti-pTau Fab reveals how germline substitutions humanize CDRs without loss of binding’
Brinth, A. R., Svenson, K., Mosyak, L., Cunningham, O., Hickling, T. P., & Lambert, M. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-12838-6 · Cited by 2
Immobilised enzyme cascade for targeted glycosylation
Makrydaki, E., Donini, R., Krueger, A., Royle, K., Moya-Ramírez, I., Kuntz, D., Rose, D., Haslam, S., Polizzi, K., & Kontoravdi, C. (2022) · bioRxiv · doi:10.1101/2022.04.08.487553 · Cited by 2
Kinetic and molecular insight into immunoglobulin G binding to immobilized recombinant protein A of different orientations.
Chu, X., Yang, X., Shi, Q.-H., Dong, X., & Sun, Y. (2022) · Journal of Chromatography A · doi:10.1016/j.chroma.2022.463040 · Cited by 2
A Review on Empirical Approach to Therapeutic Recombinant Protein Production Factories: Applications, Pharmacokinetics and Challenges
Naz, Z., Kanwal, A., & Tayyeb, A. (2022) · Journal of Bioresource Management · doi:10.35691/jbm.2202.0222 · Cited by 2
Bioprocess Intensification: Technologies and Goals
Whitford, W. (2021) · Process Control, Intensification, and Digitalisation in Continuous Biomanufacturing · doi:10.1002/9783527827343.ch4 · Cited by 2
Consistent Value Creation from Bioprocess Data with Customized Algorithms: Opportunities Beyond Multivariate Analysis
Narayanan, H., von Stosch, M., Luna, M. F., Bournazou, M. N. C., Butté, A., & Sokolov, M. (2021) · Wiley eBooks · doi:10.1002/9783527827343.ch8 · Cited by 2
Rapid Antibody Glycoengineering in CHO Cells Via RNA Interference and CGE-LIF N-Glycomics
Kotidis, P., Marbiah, M. M., Donini, R., Gómez, I. A., del Val, I. J., Haslam, S. M., Polizzi, K. M., & Kontoravdi, C. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1685-7_7 · Cited by 3
Using targeted genome integration for virus-free genome-wide mammalian CRISPR screen
Xiong, K., Karottki, K. J. L. C., Hefzi, H., Li, S.-Y., Grav, L. M., Li, S.-Z., Spahn, P. N., Lee, J. S., Lee, G., Kildegaard, H., et al. (2020) · bioRxiv · doi:10.1101/2020.05.19.103648 · Cited by 2
Serum‐free suspension cultured human cells can produce a high‐level of recombinant human erythropoietin
Silva, L. C., dos Santos, M. H., Heluy, T. R., Biaggio, R. T., Ferreira, A. R., Milhomens, J., Kashima, S. H., Nemer, W. E., Hoss, S. E., Picanço‐Castro, V., et al. (2020) · Engineering Reports · doi:10.1002/eng2.12172 · Cited by 3
“3 The main structural differences between recombinant proteins produced in nonhuman vs human mammalian cells include the presence of the nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc) and the absence of α(2,6) linkages of sialic acid to galactose.”
Background
Agave salmiana syrup improves the production of recombinant human interleukin-2 in Escherichia coli
Balderas-Hernández, V., Medina-Rivero, E., la Rosa, A. P. B., & León-Rodríguez, A. D. (2020) · doi:10.24275/rmiq/bio2004 · Cited by 2
“E. coli remains as a model host for production of recombinant proteins, as around 30 to 40% of the approved therapeutic proteins are currently produced using this expression system (Baeshen et al., 2015; Walsh 2018).”
Background
Quantification of the dynamics of population heterogeneities in CHO cultures with stably integrated fluorescent markers
Möller, J., Rosenberg, M., Riecken, K., Pörtner, R., Zeng, A., & Jandt, U. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-020-02401-5 · Cited by 7
Role of Business Models in Funding the Biotech Industry: Global Trends and Challenges for Cuban Biotechnology.
Blanco-García, E. (2020) · MEDICC Review · doi:10.37757/mr2020.v22.n1.4 · Cited by 2
“5 years from January 2015 to July 2018, 112 new biological products were registered.[1] True, this period coincided with the emergence of biosimilars, which increased the number of registrations by 59% compared to the previous 5-year period (2010–2014), but novel products saw similar growth (52%).”
BackgroundResultInfluential
Technological advancement in the development of monoclonal antibody therapies: Present, past, and future
Kasana, H., Chander, H., & Mathur, A. (2024) · Journal of Applied Biology & Biotechnology · doi:10.7324/jabb.2024.172190 · Cited by 1
“Keytruda, which is a drug developed by Merck and introduced in 2014, garnered USD 20.9 billion in sales in 2022 [16].”
BackgroundInfluential
Duckweeds for the Production of Therapeutic Proteins
Khvatkov, P., Firsov, A., Mitiouchkina, T., Chernobrovkina, M., & Dolgov, S. (2021) · doi:10.1007/978-3-030-58271-5_5 · Cited by 2
Development of recombinase-based targeted integration systems for production of exogenous proteins using transposon-mediated landing pads
Reese, N., & Ku, S. (2021) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2021.10.001 · Cited by 2
Redesigning Spent Media from Cell Culture Bioprocess to Feed New Bacterial Fermentations
Lynch, C. D., Jordan, L., & O’Connell, D. J. (2021) · Cell engineering · doi:10.1007/978-3-030-79871-0_5 · Cited by 2
Monitoring Tools for the Development of High Cell Density Culture Strategies
Lecina, M., Comas, P., Martínez‐Monge, I., & Cairó, J. J. (2021) · Cell engineering · doi:10.1007/978-3-030-79871-0_16 · Cited by 2
Advances in Membrane Proteins: Building, Signaling and Malfunction
Cao, Y., Jiang, X., Chen, Y., & Xia, Y. (2019) · doi:10.1007/978-981-13-9077-7 · Cited by 2
Glycosylation-on-a-Chip: A Flow-Based Microfluidic System for Cell-Free Glycoprotein Biosynthesis
Aquino, A., Manzer, Z., Daniel, S., & DeLisa, M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.782905 · Cited by 1
Microbe-specific and product-specific strategies for scalable biomanufacturing
Wang, S., Li, Z., Hu, P., Wang, Q., Chen, F., & Xu, P. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.109000 · Cited by 1
Dynamic Simulation and Optimisation of a Fed-Batch Bioreactor for mAbs Under Varying Substrate and Feed Flow Conditions
Abidi, F., Jones, W., & Gerogiorgis, D. (2026) · Processes · doi:10.3390/pr14142322 · Cited by 1
Extracellular vesicle depletion improves transient gene expression performance and alters cellular transcriptional responses in CHO cell
Rahimi, M., Pérez‐Rubio, P., Vargas-Gracia, J., Kempen, P. J., Nielsen, L. K., & Lavado‐García, J. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119749 · Cited by 1
Molecular Engineering of the Nano‐Bio Interface for Programmable and Precision Protein Delivery
Tc, M., Yao, R., Zhang, Q., & Wang, M. (2026) · Advanced Materials · doi:10.1002/adma.73544
Artificial induction of bottlenecks in the endoplasmic reticulum for rational improvement of antibody secretion in Chinese hamster ovary cells
Tsunoda, Y., Somatani, A., Yoshiike, C., Mitoma, S., Yamano, N., & Ōmasa, T. (2026) · New Biotechnology · doi:10.1016/j.nbt.2026.05.010 · Cited by 1
Preparation, Interaction Mechanism and Application of Functional Ionic Liquid-Mediated Protein Imprinting Technique
Zhang, N., Zhang, J.-R., Yu, K., Qiao, Y., Cui, P., Yang, C., & Li, M.-L. (2026) · Polymers · doi:10.3390/polym18101171 · Cited by 1
“Proteomics is one of the leading disciplines in the field of life sciences, which has attracted considerable attention in biomedicine, immunoassay diagnosis, biosensing and other fields in recent years [1,2].”

Authors: Walsh, G.
Affiliations: University of Limerick (IE)
Corresponding author: Walsh, Gary
ORCID: Walsh, Gary
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2018-12
Volume: 36
Issue: 12
Pages: 1136-1145
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.4305
OpenAlex: W2917928050
Cited by: 978
References: 15
Citations by year: 2026: 68 · 2025: 68 · 2024: 88 · 2023: 141 · 2022: 173 · 2021: 197 · 2020: 173 · 2019: 65
FWCI: 165.34
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords: biopharmaceutical market, monoclonal antibodies, cell therapy, gene therapy, biosimilars, biologics, market growth
MeSH terms: Animals, Antibodies, Monoclonal, Biological Products, Biotechnology, Drug Industry, European Union, Humans, Nucleic Acids, Recombinant Proteins, United States, United States Food and Drug Administration, Drug Approval, Benchmarking, Biosimilar Pharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Biopharmaceutical benchmarks 2018

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks